Improvement of the osteogenic potential of ErhBMP-2-/EGCG-coated biphasic calcium phosphate bone substitute: in vitro and in vivo activity
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate the enhancement of osteogenic potential of biphasic calcium phosphate (BCP) bone substitute coated with Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2) and epigallocatechin-3-gallate (EGCG). Methods: The cell viability, differentiation, and mineralization of osteoblasts was tested with ErhBMP-2-/EGCG solution. Coated BCP surfaces were also investigated. Standardized, 6-mm diameter defects were created bilaterally on the maxillary sinus of 10 male New Zealand white rabbits. After removal of the bony windows and elevation of sinus membranes, ErhBMP-2-/EGCG-coated BCP was applied on one defect in the test group. BCP was applied on the other defect to form the control group. The animals were sacrificed at 4 or 8 weeks after surgery. Histologic and histometric analyses of the augmented graft and surrounding tissue were performed. Results: The 4-week and 8-week test groups showed more new bone (%) than the corresponding control groups (P<0.05). The 8-week test group showed more new bone (%) than the 4-week test group (P<0.05). Conclusions: ErhBMP-2-/EGCG-coated BCP was effective as a bone graft material, showing enhanced osteogenic potential and minimal side effects in a rabbit sinus augmentation model.
Abstract
Purpose: The aim of this study was to evaluate the enhancement of osteogenic potential of biphasic calcium phosphate (BCP) bone substitute coated with Escherichia coli-derived recombinant human bone morphogenetic protein-2 (ErhBMP-2) and epigallocatechin-3-gallate (EGCG). Methods: The cell viability, differentiation, and mineralization of osteoblasts was tested with ErhBMP-2-/EGCG solution. Coated BCP surfaces were also investigated. Standardized, 6-mm diameter defects were created bilaterally on the maxillary sinus of 10 male New Zealand white rabbits. After removal of the bony windows and elevation of sinus membranes, ErhBMP-2-/EGCG-coated BCP was applied on one defect in the test group. BCP was applied on the other defect to form the control group. The animals were sacrificed at 4 or 8 weeks after surgery. Histologic and histometric analyses of the augmented graft and surrounding tissue were performed. Results: The 4-week and 8-week test groups showed more new bone (%) than the corresponding control groups (P<0.05). The 8-week test group showed more new bone (%) than the 4-week test group (P<0.05). Conclusions: ErhBMP-2-/EGCG-coated BCP was effective as a bone graft material, showing enhanced osteogenic potential and minimal side effects in a rabbit sinus augmentation model.
참고문헌 (30)
- Bessho K, "Bone induction by Escherichia coli-derived recombinant human bone morphogenetic protein-2 compared with Chinese hamster ovary cell-derived recombinant human bone morphogenetic protein-2", Br J Oral Maxillofac Surg, 38, pp.645~649 (2000)
- Lee JH, "The induction of bone formation in rat calvarial defects and subcutaneous tissues by recombinant human BMP-2, produced in Escherichia coli", Biomaterials, 31, pp.3512~3519 (2010)
- Long S, "Expression, purification, and renaturation of bone morphogenetic protein-2 from Escherichia coli", Protein Expr Purif, 46, pp.374~378 (2006)
- Vallejo LF, "Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli", J Biotechnol, 94, pp.185~194 (2002)
- 최경희, "E. coli 발현 시스템에 의해 생산된 recombinant human bone morphogenetic protein-2의 정제와 생물학적 활성", Journal of Periodontal & Implant Science, 38(1), pp.41~50 (2008), 대한치주과학회
- Wong DA, "Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF", TLIF use of bone morphogenetic protein-2 (BMP2), 2008, pp.8, 1011~1018
- Kaneko H, "Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts", Bone, 27, pp.479~486 (2000)
- Smucker JD, "Increased swelling complications associated with offlabel usage of rhBMP-2 in the anterior cervical spine", Spine(Phila Pa 1976), 31, pp.2813~2819 (2006)
- 최현민, "Improvement of osteogenic potential of biphasic calcium phosphate bone substitute coated with two concentrations of expressed recombinant human bone morphogenetic protein 2", Journal of Periodontal & Implant Science, 42(4), pp.119~126 (2012), 대한치주과학회[DOI]
- Yang CS, "Effects of tea consumption on nutrition and health", J Nutr, 130, pp.2409~2412 (2000)
- Tosetti F, "Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals", Int J Cancer, 125, pp.1997~2003 (2009)
- Rahman I, "Regulation of inflammation and redox signaling by dietary polyphenols", Biochem Pharmacol, 72, pp.1439~1452 (2006)
- Nakagawa H, "Fenton reaction is primarily involved in a mechanism of (-)-epigallocatechin-3-gallate to induce osteoclastic cell death", Biochem Biophys Res Commun, 292, pp.94~101 (2002)
- Yun JH, "Inhibitory effects of green tea polyphenol (-)-epigallocatechin gallate on the expression of matrix metalloproteinase-9 and on the formation of osteoclasts", J Periodontal Res, 39, pp.300~307 (2004)
- Vali B, "Epigallocatechin-3-gallate increases the formation of mineralized bone nodules by human osteoblast-like cells", J Nutr Biochem, 18, pp.341~347 (2007)
- Tokuda H, "(-)-Epigallocatechin gallate inhibits basic fibroblast growth factor-stimulated interleukin-6 synthesis in osteoblasts", Horm Metab Res, 40, pp.674~678 (2008)
- Tokuda H, "(--)-Epigallocatechin gallate enhances prostaglandin F2alpha-induced VEGF synthesis via upregulating SAPK", JNK activation in osteoblasts, 2007, pp.100, 1146~1153
- Kato K, "(-)-Epigallocatechin gallate inhibits thyroid hormone-stimulated osteocalcin synthesis in osteoblasts", Mol Med Rep, 4, pp.297~300 (2011)
- Kim S, "Effects of biphasic calcium phosphate bone substitute on circumferential bone defects around dental implants in dogs", Int J Oral Maxillofac Implants, 26, pp.265~273 (2011)
- Daculsi G, "Current state of the art of biphasic calcium phosphate bioceramics", J Mater Sci Mater Med, 14, pp.195~200 (2003)
- 최현민, "Improvement of osteogenic potential of biphasic calcium phosphate bone substitute coated with synthetic cell binding peptide sequences", Journal of Periodontal & Implant Science, 42(5), pp.166~172 (2012), 대한치주과학회
- Shin YS, "The effects of ErhBMP-2-", EGCG-coated BCP bone substitute on dehiscence around dental implants in dogs, 2014, pp.20, 281~287
- Xiao SJ, "Covalent attachment of cell-adhesive, (Arg-Gly-Asp)-containing peptides to titanium surfaces", Langmuir, 14, pp.5507~5516 (1998)
- Durrieu MC, "Grafting RGD containing peptides onto hydroxyapatite to promote osteoblastic cells adhesion", J Mater Sci Mater Med, 15, pp.779~786 (2004)
- Choi Y, "Sinus augmentation using absorbable collagen sponge loaded with Escherichia coli-expressed recombinant human bone morphogenetic protein 2 in a standardized rabbit sinus model: a radiographic and histologic analysis", Clin Oral Implants Res, 23, pp.682~689 (2012)
- Misch CE, "Contemporary implant dentistry" (1999), Mosby
- Yun JH, "(-)-Epigallocatechin gallate induces apoptosis, via caspase activation, in osteoclasts differentiated from RAW 264.7 cells", J Periodontal Res, 42, pp.212~218 (2007)
- Xu H, "Histomorphometric study of the stability of newly formed bone after elevation of the floor of the maxillary sinus", Br J Oral Maxillofac Surg, 43, pp.493~499 (2005)
- Asai S, "Maxillary sinus augmentation model in rabbits: effect of occluded nasal ostium on new bone formation", Clin Oral Implants Res, 13, pp.405~409 (2002)
- Frenken JW, "The use of Straumann Bone Ceramic in a maxillary sinus floor elevation procedure: a clinical, radiological, histological and histomorphometric evaluation with a 6-month healing period", Clin Oral Implants Res, 21, pp.201~208 (2010)
